World's Best Scientists 2026 revealed!
Masahiro Fukuoka

Masahiro Fukuoka

D-Index & Metrics

Medicine

D-Index
89
Citations
52279
World Ranking
12422
National Ranking
366

Masahiro Fukuoka publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Masahiro Fukuoka sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 619 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Masahiro Fukuoka D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Masahiro Fukuoka sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Masahiro Fukuoka is affiliated with Kindai University in Japan, focusing on medical research predominantly related to imaging, diagnostics, and treatment within cardiology and oncology. Their work spans several specialized subfields and topics in medicine, with a concentration on advanced imaging techniques and clinical applications.

The scientist has contributed research in the main field of Medicine, with particular specialization in:

  • Radiology, Nuclear Medicine and Imaging
  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cardiology and Cardiovascular Medicine
  • Orthopedics and Sports Medicine

Fukuoka's research topics cover a range of clinically relevant areas, emphasizing cardiac and lung conditions, including:

  • Cardiac Imaging and Diagnostics
  • Advanced MRI Techniques and Applications
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Cardiovascular Function and Risk Factors
  • Cardiac Arrhythmias and Treatments

The scientist has published multiple papers in recognized medical journals. Recent publications include:

  • "Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study" (2020), published in Lung Cancer
  • "Relationship between cardiac magnetic resonance derived extracellular volume fraction and myocardial strain in patients with non-ischemic dilated cardiomyopathy" (2020), published in European Heart Journal
  • "Extracellular volume fraction by T1 mapping predicts improvement of left ventricular ejection fraction after catheter ablation in patients with non-ischemic cardiomyopathy and atrial fibrillation" (2020), published in European Heart Journal
  • "Migratory bone lesions in lymphoma" (2022), published in QJM

Frequent publication venues for Fukuoka's work include:

  • European Heart Journal
  • Lung Cancer
  • QJM

Collaborative efforts are a notable part of Fukuoka's research activity. Frequent co-authors include:

  • Nobuyuki Yamamoto
  • Mai Azuma
  • Shingo Kato
  • S Kodama
  • Keigo Hayakawa

Best Publications

  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

    Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Tetsuya Mitsudomi;Satoshi Morita;Yasushi Yatabe;Shunichi Negoro

  • Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non–Small-Cell Lung Cancer

    Kiyoyuki Furuse;Masahiro Fukuoka;Masaaki Kawahara;Hideki Nishikawa

  • Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

    Kazumasa Noda;Yutaka Nishiwaki;Masaaki Kawahara;Shunichi Negoro

  • Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

    Masahiro Fukuoka;Yi Long Wu;Sumitra Thongprasert;Patrapim Sunpaweravong

  • Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

    Takashi Seto;Terufumi Kato;Makoto Nishio;Koichi Goto

  • Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

    Daphne W. Bell;Thomas J. Lynch;Sara M. Haserlat;Patricia L. Harris

  • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

    Y Ohe;Y Ohashi;K Kubota;T Tamura

  • Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

    Minoru Takada;Masahiro Fukuoka;Masaaki Kawahara;Takahiko Sugiura

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

    Kimio Yonesaka;Kreshnik Zejnullahu;Isamu Okamoto;Taroh Satoh

  • CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

    Noriyuki Masuda;Masahiro Fukuoka;Yoko Kusunoki;Kaoru Matsui

  • A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.

    M Fukuoka;H Niitani;A Suzuki;M Motomiya

  • Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

    Masahiro Fukuoka;Kiyoyuki Furuse;Nagahiro Saijo;Yutaka Nishiwaki

  • Gefitinib--a novel targeted approach to treating cancer.

    Roy S. Herbst;Masahiro Fukuoka;José Baselga

  • Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

    Riichiroh Maruyama;Yutaka Nishiwaki;Tomohide Tamura;Nobuyuki Yamamoto

  • Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

    Shinzoh Kudoh;Koji Takeda;Kazuhiko Nakagawa;Minoru Takada

  • Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

    Shoji Kudoh;Harubumi Kato;Yutaka Nishiwaki;Masahiro Fukuoka

  • Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

    Masahiko Ando;Isamu Okamoto;Nobuyuki Yamamoto;Koji Takeda

  • Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

    Shunichi Negoro;Masahiro Fukuoka;Noriyuki Masuda;Minoru Takada

Frequent Co-Authors

Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Isamu Okamoto
Isamu Okamoto Kyushu University
Yutaka Nishiwaki
Yutaka Nishiwaki Tokyo Medical University
Nagahiro Saijo
Nagahiro Saijo AstraZeneca (United Kingdom)
Tomohide Tamura
Tomohide Tamura St. Luke's International Hospital
Yuichiro Ohe
Yuichiro Ohe National Cancer Centre
Kazuto Nishio
Kazuto Nishio Kindai University
Satoshi Morita
Satoshi Morita Kyoto University
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Tony Mok
Tony Mok Chinese University of Hong Kong

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Students interested in Medicine may also want to explore flexible online degree options that open diverse career pathways within healthcare. For those seeking leadership roles, consider an accelerated healthcare administration degree online to quickly gain business and management skills relevant to hospitals and healthcare organizations.

Registered nurses (RNs) looking to advance in clinical practice can consider rn to np programs online, which bridge the gap to a nurse practitioner role. These programs are ideal for working professionals aiming to deepen their clinical expertise and expand patient care options.

If nutrition and wellness are your focus, pursuing an online dietitian degree can prepare you for careers in dietetics, nutrition counseling, and more.

Aspiring healthcare executives should look for a cahme accredited online mha to ensure a high-quality, professionally recognized education in healthcare administration.

These online options provide flexible, accredited pathways to specialized roles, supporting both career changers and current healthcare workers seeking advancement.

Best Scientists Citing Masahiro Fukuoka

Trending Scientists

Recently Published Articles